Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2000
11/16/2000CA2371472A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
11/16/2000CA2371469A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2371095A1 Enhanced delivery of nucleic acid-based drugs
11/16/2000CA2370838A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2370801A1 1,5-benzodiazepine derivatives as cck-a receptor agonists
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000CA2369328A1 Drug delivery device
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000CA2368831A1 Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/16/2000CA2366201A1 Use of selective antagonists of the .alpha.1b-adrenergic receptor for improvement of sexual dysfunction
11/15/2000EP1052286A2 Growth hormone and growth hormone releasing hormone compositions
11/15/2000EP1052259A1 Novel optically active aminopentane derivative
11/15/2000EP1052255A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics.
11/15/2000EP1052254A1 Nitrogenous heterocyclic derivatives and medicine thereof
11/15/2000EP1052250A1 Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
11/15/2000EP1052245A2 High purity (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them
11/15/2000EP1052243A2 Process for preparing (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof
11/15/2000EP1052238A1 Novel tricyclic compound
11/15/2000EP1051995A2 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051994A2 5HT1 receptor agonists and a cox-2 inhibitor for the treatment of migraine
11/15/2000EP1051993A2 5HT1 receptor agonists and either a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051980A2 Dopamine transporter imaging agents
11/15/2000EP1051979A1 Use of peroxidised lipids to prevent and/or treat the irritating effect of an active agent
11/15/2000EP1051978A1 Crystallographically stable amorphous cephalosporin compositions and process for producing the same
11/15/2000EP1051976A2 Use of bisphosphate for the treatment of osteogenesis imperfecta
11/15/2000EP1051975A1 Dry mix formulation for bisphosphonic acids
11/15/2000EP1051973A1 Optic papillary circulation improving agents
11/15/2000EP1051972A1 Nitric oxide donor composition and method for treatment of anal disorders
11/15/2000EP1051971A1 Patch and method for transdermal delivery of bupropion base
11/15/2000EP1051655A1 Methods and apparatus for accelerated orthokeratology
11/15/2000EP1051521A2 Method of screening therapeutic agents
11/15/2000EP1051511A1 Methods of identifying modulators of kinases responsive to stress
11/15/2000EP1051500A2 Diagnosis and treatment of aur1 and/or aur2 related disorders
11/15/2000EP1051486A1 Gtpase derived from human lymph nodes that effects the morphology and cytoskeleton organization of endothelial cells
11/15/2000EP1051479A1 Novel steroid-activated nuclear receptors and uses therefor
11/15/2000EP1051429A1 Ldl related protein and uses thereof
11/15/2000EP1051425A2 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES
11/15/2000EP1051420A1 New cytotoxic tris(oxazole)-containing macrolides
11/15/2000EP1051419A1 Deprotection and recrystallization processes
11/15/2000EP1051416A1 1,4-diazacycloheptane derivatives for the treatment of neurological disorders
11/15/2000EP1051415A1 Benzamide derivatives as vasopressin antagonists
11/15/2000EP1051413A1 Quinoline derivatives as antibacterials
11/15/2000EP1051412A1 Methods for separating a tocotrienol from a tocol-containing mixture and compositions thereof
11/15/2000EP1051411A1 Methods for separating a tocol from a tocol-containing mixture
11/15/2000EP1051410A1 Benzo[b]pyran derivatives useful as external agents for the skin
11/15/2000EP1051407A1 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
11/15/2000EP1051405A2 Novel dihydroxyhexanoic acid derivatives
11/15/2000EP1051403A1 Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
11/15/2000EP1051399A1 Phenylalanine derivatives useful as pharmaceutical agents
11/15/2000EP1051398A1 Thermodynamically stable form of (r)-3- (4-fluorophenyl) sulphonyl]amino] -1,2,3,4- tetrahydro -9h-carbazole -9-propanoic acid (ramatroban)
11/15/2000EP1051395A1 Hydroxamic and carboxylic acid derivatives
11/15/2000EP1051394A1 Potassium channel inhibitors
11/15/2000EP1051393A1 New derivatives of sulfonic, phosphonic and phosphinic aminoalkane acids, their production and their use as medicaments
11/15/2000EP1051392A1 Adamantanecarboximidamide derivatives and their use as nmda antagonists
11/15/2000EP1051387A1 Anticancer platinum (iv) complexes for oral administration
11/15/2000EP1051383A1 Hydroxylation activated prodrugs
11/15/2000EP1051208A1 Hydrophilic coating for an intracorporeal medical device
11/15/2000EP1051195A1 Identification of agents that protect against inflammatory injury to neurons
11/15/2000EP1051193A1 Anhydrous topical skin preparations
11/15/2000EP1051192A2 Methods for the prevention and treatment of fibrosis and sclerosis
11/15/2000EP1051186A2 Synergistic mixtures of garlic and lycopene for preventing ldl oxidation
11/15/2000EP1051183A1 Peritoneal dialysis solution containing modified icodextrins
11/15/2000EP1051182A1 Methods of decreasing or preventing pain using spicamycin or derivatives thereof
11/15/2000EP1051181A2 Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
11/15/2000EP1051180A1 Phospholipids having antimicrobial activity with or without the presence of antimicrobials
11/15/2000EP1051179A2 Anti-estrogen plus progestin containing oral contraceptives
11/15/2000EP1051178A1 Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase
11/15/2000EP1051177A1 Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase
11/15/2000EP1051176A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
11/15/2000EP1051175A1 Use of bicozamycin for the manufacture of a medicament for treating infections with enterohemorrhagic e. coli
11/15/2000EP1051174A1 Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations
11/15/2000EP1051173A1 Derivatives of 1,3,4-oxadiazolone
11/15/2000EP1051172A2 Method for treating copd
11/15/2000EP1051171A1 Isoflavanoid formulations for oral administration
11/15/2000EP1051170A1 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
11/15/2000EP1051169A1 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
11/15/2000EP1051168A2 Compositions, apparatus and methods for facilitating surgical procedures
11/15/2000EP1051167A1 Pharmaceutical uses of optically pure (-) -bupropion
11/15/2000EP1051166A1 Pharmaceutical uses of optically pure (+) -bupropion
11/15/2000EP1051165A2 Mitochondria protecting agents for treating mitochondria associated diseases
11/15/2000EP1051164A1 Pharmacological uses of pure (+) -bupropion
11/15/2000EP1051163A2 Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
11/15/2000EP1051162A1 Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
11/15/2000EP1051161A1 Method for treating alzheimer's disease
11/15/2000EP1051160A1 Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process
11/15/2000EP1051159A1 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
11/15/2000EP1051156A2 Pharmaceutical compositions
11/15/2000EP1051155A1 Nasal solutions
11/15/2000EP1051150A1 Anti-enzyme compositions comprising ethylenediamine disuccinic acid
11/15/2000EP0923378A4 Promotion of wound healing by chemically-modified tetracyclines
11/15/2000EP0904071B1 Oral rehydration product comprising glutamine
11/15/2000EP0725639B1 A stable pharmaceutical composition of terfenadine and ibuprofen
11/15/2000EP0697169B1 Organ preservative
11/15/2000EP0691847B1 Use of aspirin for the manufacture of a medicament for enhancing uterine blood perfusion
11/15/2000CN1273587A Process for preparation of 3-cephem compounds
11/15/2000CN1273584A Imidazolyl-cyclic acetals
11/15/2000CN1273581A Method and reagents for N-alkylating ureides
11/15/2000CN1273580A Styryl sulfone anticancer agents
11/15/2000CN1273579A Anthranilic acid analogs
11/15/2000CN1273532A Bovine excretion extracts having anticancer and anti-inflammatory activity and process for preparing the same
1 ... 6209 6210 6211 6212 6213 6214 6215 6216 6217 6218 6219 6220 6221 6222 6223 6224 6225 6226 6227 6228 6229 ... 7860